Login to Your Account



Clinic Roundup


Friday, March 8, 2013
• ADMA Biologics Inc., of Hackensack, N.J., enrolled its first patient in a Phase III trial of RI-002, an immune globulin, for primary immune deficiency diseases (PIDD). The trial will enroll 60 to 70 patients for a 12-month treatment period followed by up to 90 days safety monitoring and follow-up. Its goal will be to evaluate safety and efficacy of the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription